Castle Biosciences Inc
NASDAQ:CSTL

Watchlist Manager
Castle Biosciences Inc Logo
Castle Biosciences Inc
NASDAQ:CSTL
Watchlist
Price: 29.81 USD 3.22% Market Closed
Market Cap: 835m USD
Have any thoughts about
Castle Biosciences Inc?
Write Note

Operating Margin
Castle Biosciences Inc

-0.3%
Current
-43%
Average
4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-0.3%
=
Operating Profit
-1m
/
Revenue
311.9m

Operating Margin Across Competitors

Country US
Market Cap 834m USD
Operating Margin
0%
Country US
Market Cap 91.8B USD
Operating Margin
4%
Country US
Market Cap 87.7B EUR
Operating Margin
4%
Country US
Market Cap 73B USD
Operating Margin
3%
Country DE
Market Cap 24.9B EUR
Operating Margin
7%
Country US
Market Cap 20.1B USD
Operating Margin
9%
Country DE
Market Cap 18.8B EUR
Operating Margin
7%
Country US
Market Cap 18.3B USD
Operating Margin
14%
Country US
Market Cap 13.7B USD
Operating Margin
15%
Country DE
Market Cap 12.4B EUR
Operating Margin
7%
Country AU
Market Cap 13.4B AUD
Operating Margin
9%
No Stocks Found

Castle Biosciences Inc
Glance View

Market Cap
834m USD
Industry
Health Care

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.

CSTL Intrinsic Value
31.49 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-0.3%
=
Operating Profit
-1m
/
Revenue
311.9m
What is the Operating Margin of Castle Biosciences Inc?

Based on Castle Biosciences Inc's most recent financial statements, the company has Operating Margin of -0.3%.